Trial
NCT01436175
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Shire
Collaborators
—
Condition
Major Depressive Disorder
Intervention
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Why stopped
SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-14